ADMETech, a technology platform-based drug discovery and development company founded by faculty at the UNC-Chapel Hill School of Pharmacy, has appointed Scott Neuville as the company’s president and chief executive officer.

Neuville, a veteran in the life sciences industry, is the former chairman and CEO of iBiomatics, a SAS company. Prior to joining iBiomatics, he spent seven years with STERIS Corp. in senior executive roles, including president of the Americas Healthcare Division. Neuville also sits on the board of directors for the Clinical Data Interchange Standards Consortium, an organization consisting of life sciences and technology companies.

“Scott Neuville brings just the right mix of strong leadership qualities, proven management experience and entrepreneurial spirit to ADMETech,” Co-founder Dhiren Thakker, a Ferguson professor of pharmaceutical sciences, said in a statement. “The company is poised to become a leader in bringing breakthrough technologies to the pharmaceutical industry.”

Formed at UNC in 1999 by Professor Kim Brouwer, Professor Gary Pollack, Thakker and Ed LeCluyse, an assistant professor in collaboration with UNC’s Office of Technology Development, ADMETech develops technologies to screen and optimize potential drug molecules based on the founders’ research in the absorption, metabolism, distribution, and excretion (ADME) processes. The company says its technologies have the potential to achieve dramatic improvements in the screening methods used to optimize drug candidates for ADME properties, ensuring greater success in clinical trials.

“ADMETech will offer the pharmaceutical industry the ability to test new compounds in a much more effective and efficient manner, thus saving millions of dollars in a development process that brings proven products to market,” Neuville said in a statement.

Neuville will focus his efforts on gaining additional funding to fuel expansion of the organization and develop ADMETech’s current and prospective technologies and client base. The new president and CEO will direct the search for a chief scientific officer while additional staff members join the company.